ERBB2 and breast cancer: [225Ac]Ac-DOTA-trastuzumab was synthesized and characterized, and the effect of treatment of HER2-positive SK-BR-3 human BC cells in vitro with [225Ac]Ac-DOTA-trastuzumab on their clonogenic survival or for causing DNA DSBs assessed.